Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $15.1 million.

  • Fortress Biotech's Cash from Financing Activities rose 45595.72% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.5 million, marking a year-over-year increase of 1027.44%. This contributed to the annual value of $70.6 million for FY2024, which is 11577.02% up from last year.
  • Latest data reveals that Fortress Biotech reported Cash from Financing Activities of $15.1 million as of Q3 2025, which was up 45595.72% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Cash from Financing Activities registered a high of $78.7 million during Q1 2021, and its lowest value of -$30.4 million during Q2 2023.
  • Moreover, its 5-year median value for Cash from Financing Activities was $18.6 million (2022), whereas its average is $21.0 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 111574.72% in 2023, then surged by 45595.72% in 2025.
  • Quarter analysis of 5 years shows Fortress Biotech's Cash from Financing Activities stood at $38.9 million in 2021, then tumbled by 52.19% to $18.6 million in 2022, then soared by 134.28% to $43.6 million in 2023, then crashed by 40.84% to $25.8 million in 2024, then plummeted by 41.59% to $15.1 million in 2025.
  • Its last three reported values are $15.1 million in Q3 2025, $4.5 million for Q2 2025, and $52.1 million during Q1 2025.